Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7

Chimeric antigen receptor (CAR)-T cell immunotherapy is a novel treatment that genetically modifies the patients’ own T cells to target and kill malignant cells. However, identification of tumour-specific antigens expressed on multiple solid cancer types, remains a major challenge. P2X purinoceptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandara, Veronika, Foeng, Jade, Gundsambuu, Batjargal, Norton, Todd S., Napoli, Silvana, McPeake, Dylan J., Tyllis, Timona S., Rohani-Rad, Elaheh, Abbott, Caitlin, Mills, Stuart J., Tan, Lih Y., Thompson, Emma J., Willet, Vasiliki M., Nikitaras, Victoria J., Zheng, Jieren, Comerford, Iain, Johnson, Adam, Coombs, Justin, Oehler, Martin K., Ricciardelli, Carmela, Cowin, Allison J., Bonder, Claudine S., Jensen, Michael, Sadlon, Timothy J., McColl, Shaun R., Barry, Simon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491676/
https://www.ncbi.nlm.nih.gov/pubmed/37684239
http://dx.doi.org/10.1038/s41467-023-41338-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491676/
https://www.ncbi.nlm.nih.gov/pubmed/37684239
http://dx.doi.org/10.1038/s41467-023-41338-y

Ejemplares similares